Published in final edited form as:

J Pediatr. 2015 April ; 166(4): 1070–1074. doi:10.1016/j.jpeds.2014.12.023.

Reappraisal of Guidelines for Management of Neonates with Suspected Early-Onset Sepsis

William E. Benitz¹, James L. Wynn², and Richard A. Polin³

¹Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University, Palo Alto, CA, USA

²Division of Neonatal-Perinatal Medicine, Department of Pediatrics, Vanderbilt University, Nashville, TN, USA

³Division of Neonatal-Perinatal Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA

Abstract

Since 1992, professional societies or public health agencies in the United States^{1–12} and elsewhere^{13–17} have issued several generations of recommendations for prevention or management of early-onset neonatal sepsis (EOS). Despite those efforts, recommendations remain inconsistent, clarifications are necessary¹⁸, local adaptations are common¹⁹, and compliance rates are low²⁰. We postulate that lack of consensus, especially regarding postnatal management of the neonate, is largely a result of two sets of factors. First, obstetrical prevention strategies have substantially reduced incidence of EOS, potentially changing the utility of predictive strategies based on risk factors. Second, recent data better delineate relationships among risk factors, clinical signs, and EOS, suggesting that risk predictors may have different utilities in different groups. The purpose of this commentary is to explore these questions and to suggest new approaches to management of newborns who may be at risk for EOS.

Keywords

Infant, newborn; infant, premature; bacterial sepsis; neonatal sepsis; practice guidelines; risk factors; risk assessment; chorioamnionitis

The evolution of neonatal sepsis risk assessment

Adoption of intrapartum antibiotic prophylaxis for prevention of early-onset group B streptococcal sepsis (EOGBS) since 1995 has resulted in an 85% reduction in the rate of culture-proven EOGBS, from approximately 1.8 per 1000 live births in the early 1990s²¹ to

Corresponding author: William E. Benitz, MD, Division of Neonatal and Developmental Medicine, 750 Welch Road, Suite 315, Palo Alto, CA 94304, Phone: (650) 723-5711, Fax: (650) 725-8351, benitzwe@stanford.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The authors declare no conflicts of interest.

fewer than 0.25 per 1000 live births²² since 2010. Comparable data for EOS of all causes also reflect a reduction in attack rate, from 2.0 – 2.5 in the late 1980s and 1990s^{23–25} to 0.8 – 1.0 per 1000 live births since 2005^{26, 27}. Among infants 34²⁸ or 35^{29, 30} weeks gestation or with birth weights > 2500 g²⁶, recent EOS rates are only 0.5 – 0.8 per 1000 live births. These much lower attack rates reflect a landscape that is fundamentally different from that extant when consensus guidelines for neonatal sepsis management were being developed 20 years ago. These changes prompt the question of whether predictive tools that had utility in the past might be less valuable now. If so, development of novel approaches better suited to current circumstances may be necessary.

Current CDC guidelines recommend diagnostic evaluation, including blood and cerebrospinal fluid cultures, and treatment with broad-spectrum antibiotics for infants who show clinical signs of sepsis⁸. Current AAP guidelines advocate the same approach for critically ill infants, but are less prescriptive with respect to infants with relatively mild findings¹². The nature and severity of clinical findings that constitute a threshold for treatment remain problematic. Many infants with mild illness become asymptomatic over the first 6 hours and can be observed safely without treatment, unless signs worsen or fail to improve. Although 80%–100% of infants with blood cultures positive for a pathogenic organism exhibit clinical signs consistent with sepsis in the first 48 hours after birth^{26, 31–34}, those signs are nonspecific. EOS rates among newborn infants with such clinical signs are low, ranging from 2.7% to 5.6%^{32, 34, 35}, corresponding to numbers needed to treat (NNT) to potentially benefit the one child with bacterial infection between 18 and 38. Thus, clinical signs of illness are reliable but inefficient for identification of babies with EOS. Reduction of unnecessary treatment in this subpopulation will require development of a rapid, sensitive diagnostic tests (likely based on early components of the innate immune response) with a strong negative predictive value for EOS. Until such a test is available, infants with significant clinical signs of possible EOS should continue to have diagnostic cultures and should be treated with antibiotics. Currently available laboratory tests (such as blood cell counts, C-reactive protein, and procalcitonin levels) are not sufficiently sensitive or specific to justify their use to decide whether to initiate or withhold empiric treatment of babies with clinical signs of illness. Use of these laboratory tests should be limited to reliance on the utility of serial normal results for identification of infants without sepsis^{36–39} to support early discontinuation of empiric treatment.

Maternal chorioamnionitis is the second risk criterion in both the CDC⁸ and AAP¹² guidelines. Both recommend treatment with broad-spectrum antibiotics when this diagnosis is made, and acknowledge challenges in using this obstetrical diagnosis to guide neonatal therapy. Early studies that linked EOS to chorioamnionitis used strict diagnostic criteria, requiring 1 or 2 clinical findings in addition to maternal fever⁴⁰. It has proven difficult to incorporate strict criteria into routine clinical practice, and the diagnosis is now often based upon observation of maternal fever alone²⁰. Lack of precision in diagnosing chorioamnionitis seriously compromises its reliability as a predictive measure.

The recommendation to treat infants exposed to chorioamnionitis was largely based on the belief that chorioamnionitis was a factor in nearly 90% of the instances in which intrapartum antibiotics had failed to prevent EOS⁴¹. More recent data suggest that fewer instances of

“failed” intrapartum prophylaxis are associated with chorioamnionitis ($< 50\%$)⁴². Only one study published before the year 2000 provided data for calculation of an overall (all birth weights) odds ratio for EOS associated with chorioamnionitis (adjusted OR 4.4, 95% confidence interval 1.2–16.1)⁴³. More recent reports indicate that the risk of EOS in infants born to women with chorioamnionitis is strongly dependent on gestational age. In three reports including 1892 infants born at ≥ 35 weeks’ gestation to mothers with clinical chorioamnionitis, the rates of EOS (positive blood culture at ≥ 72 hours of age) were only 0.47%⁴⁴, 1.24%²⁹, and 0.72%³⁰ (NNT to prevent one infection 80 – 210). In contrast, 4.8% to 16.9%^{45–49} of preterm infants exposed to chorioamnionitis develop EOS (NNT 6 – 21). None of these studies stratified risk according to presence or absence of clinical signs of illness, so the proportion of affected infants who would have been treated on that basis cannot be estimated. Among preterm infants, that proportion is likely to have been substantial, so the utility of chorioamnionitis as a screening tool in that population is uncertain. Nonetheless, treatment for chorioamnionitis-exposed preterm infants, based on the high attack rates and low NNT in that group, remains justified.

Among asymptomatic late-preterm and term infants with risk factors as defined by the CDC⁸ (including but not limited to clinical chorioamnionitis), the risk of EOS is extremely low. Hashavya et al³³ found no cases of early-onset GBS sepsis among 1413 clinically well infants. Flidel-Rimon et al³⁴ reported a single instance of a positive blood culture (in a preterm infant) among 1662 at-risk babies. Ottolini et al³² and Buckler et al⁵⁰ reported no EOS cases among 1665 and 242 at-risk infants ≥ 35 weeks’ or > 37 weeks’ gestation, respectively. Predictive utility is not enhanced by use of the more objective diagnosis of histopathologic chorioamnionitis (HCA). Cuna et al⁵¹ observed no cases of clinical or culture-proven sepsis among 284 newborn infants who had HCA but neither risk factors for nor clinical signs of infection. Among infants admitted to the NICU because of risk factors or clinical signs, there was no difference in the prevalence of EOS between those with (1 of 105) or without HCA (2 of 283). The authors concluded that histopathological examination of the placenta adds little to conventional testing in guiding decisions about discontinuation of treatment. These data make it apparent that it is time to abandon the policy of treating well-appearing infants ≥ 34 weeks’ gestation because of chorioamnionitis alone.

Investigators in Boston and Northern California have taken the lead in implementing a change in practice. Recognizing the potential inconsistency in making the diagnosis of chorioamnionitis, they have chosen to rely upon maternal fever alone as a surrogate for the risk associated with chorioamnionitis¹⁹. Using data from more than 600,000 infants ≥ 34 weeks’ gestation at birth, they developed a model for EOS risk prediction based on maternal factors (gestational age, GBS colonization, duration of ruptured membranes, highest intrapartum temperature, and nature and duration of intrapartum antibiotics)⁵², and then combined that model with findings from examination of the infants²⁸ to stratify subgroups according to EOS attack rates (Table I). Sequential selection of subgroups for empiric treatment, in order of increasing NNT (Table II), demonstrates a trade-off between the proportion of cases included in the treatment group and the overall NNT, implying that the practitioner must either treat a very large proportion of the population (large NNT) or fail to achieve early treatment of a large fraction of the cases (high false-negative rate). In the latter case, close clinical monitoring will be necessary to identify untreated infants who develop

clinical signs of sepsis. The observation that even such optimal utilization of information about maternal risk factors fails to yield an efficient and highly effective ascertainment strategy²⁸ should prompt consideration of alternative approaches.

Reports of reliance on serial examination rather than risk factors or screening laboratory tests are emerging from the United States³², Israel^{33, 34}, and Italy^{35, 53} (Table III), showing that: (1) the risk of EOS is very small in well-appearing late-preterm and term infants (the sole asymptomatic baby with sepsis in these reports was a preterm infant exposed to chorioamnionitis³⁴); and (2) in well-appearing infants identified as “at-risk” based on maternal findings, laboratory screening tests have poor specificity, a low positive predictive value, and add very little diagnostic information. Reliance on serial examinations did not increase the interval between onset of clinical signs and initiation of treatment³⁵. The low case-mortality rate (1.1%) reported by Escobar et al, despite the large proportion of cases that were recognized only after development of clinical signs, suggests that diagnosis based on clinical findings does not markedly increase mortality risk²⁸. Notably, only 3 of 55 infants with EOS who were assigned to the observational protocol in that experience presented with sudden collapse; it is not apparent whether more frequent examinations might have averted those more severe findings, but it is clear that risk factors failed to identify infants with EOS. These experiences cast substantial doubt on the utility of risk factors and laboratory testing for ascertainment of EOS in late-preterm and term infants, and indicate that reliance on serial examinations alone may be safe and effective. Furthermore, simple serial examinations can be performed by bedside nursing staff, with physician notification should signs of illness develop^{35, 53}. Adoption of such approaches will require strong assurance that frequent examinations actually are performed, particularly over the first 24 hours. Early hospital discharge practices therefore may be a substantial impediment to implementation.

Conclusions

The changing environment and new data require reappraisal of traditional approaches to management of infants at risk for sepsis, with willingness to question and abandon, if necessary, longheld assumptions. Neither identification of maternal risk factors nor screening using laboratory testing is an effective strategy for ascertainment of infants with EOS in the current era. Recommendation of such approaches in current CDC and AAP recommendations should not prohibit development and adoption of alternative approaches that are better suited to current knowledge and conditions. On the contrary, such innovation should be strongly encouraged, and should be informed by the following principles:

1. Obstetrical interventions to prevent EOS are effective and should be continued.
2. Babies who exhibit persistent, progressive, or moderately severe to severe clinical signs consistent with EOS should receive empiric antibiotic therapy after cultures are obtained. Infants with mild to moderate respiratory findings (flaring, grunting, retractions, or tachypnea) immediately after birth may be monitored closely for resolution of transitional behaviors, without initiation of antibiotic treatment unless signs worsen or persist for more than 6 hours.

3. A rapid diagnostic test with a high sensitivity and negative predictive value early in the course of suspected illness offers the best opportunity for reduction of unnecessary treatment of symptomatic infants who are at low risk for EOS. Efforts to develop such tests should be sustained
4. Preterm infants (< 34 weeks' gestation or < 1500 g) are at significantly increased risk for EOS. Additional data are needed to ascertain the independent roles of maternal risk factors (including chorioamnionitis), clinical signs of illness, and laboratory findings in guiding empiric antibiotic therapy. Until such data are available, it is reasonable to continue to stratify risk based on those traditional risk factors. Because most preterm infants have clinical signs of illness, most will qualify for empiric treatment. Preterm infants who appear well and have minimal or no risk factors (e.g., no chorioamnionitis, preterm premature rupture of membranes, or GBS colonization with inadequate intrapartum prophylaxis) may be candidates for close monitoring and serial laboratory evaluation.
5. Well-appearing late-preterm and term infants should be managed with close clinical observation, because of the low sensitivity of risk factors in ascertainment of EOS in this group. Efforts to improve ascertainment of EOS cases in this population are commendable, but should not obscure the limited utility of the strategies attempted to date.
6. Even with selective treatment strategies, most treated infants will not have bacterial infection. In treated infants, serial normal diagnostic tests, such as blood counts or C-reactive protein levels are highly predictive of the absence of infection and should be relied upon (in addition to pretreatment with culture results) to minimize the duration antibiotic exposure. However, isolated abnormal hematological or acute-phase-reactant measurements should not justify continuation of empiric antibiotics for more than 48 hours in well-appearing infants with negative culture results.
7. Implementation of novel strategies for ascertainment and treatment of EOS in late preterm and term infants should be incremental and accompanied by close surveillance for both safety and efficacy.
8. Prospective capture of detailed information regarding risk factors, clinical signs, and laboratory findings in newborn infants, as now enabled by electronic medical records, should be an operational priority. Correlation of these data with outcomes attributable to bacterial sepsis, especially among preterm infants, will allow further refinement of ascertainment and treatment strategies.

Acknowledgments

J.W. is supported by the National Institutes of Health/ National Institute of General Medical Sciences (GM106143).

Abbreviations

AAP American Academy of Pediatrics

CDC	Centers for Disease Control and Prevention
EOGBS	Early onset group B streptococcal sepsis
EOS	Early onset sepsis
HCA	Histologic chorioamnionitis
NNT	Number needed to treat
OR	Odds ratio

REFERENCES

1. Committee on Infectious Diseases, Committee on Fetus and Newborn. Guidelines for prevention of group B streptococcal (GBS) infection by chemoprophylaxis. *Pediatrics*. 1992; 90:775–778. [PubMed: 1408555]
2. Committee on Technical Bulletins. Group B streptococcal infections in pregnancy. ACOG Technical Bulletin Number 170. *Int J Gynaecol Obstet*. 1993; 42:55–59. [PubMed: 8103484]
3. Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease: A public health perspective. *MMWR Recomm Rep*. 1996; 45(RR-7):1–24.
4. Committee on Obstetric Practice. Prevention of early-onset group B streptococcal disease in newborns. ACOG Committee Opinion Number 173. *Int J Gynaecol Obstet*. 1996; 54:197–205. [PubMed: 9236325]
5. Committee on Infectious Diseases, Committee on Fetus and Newborn. Revised guidelines for prevention of early-onset group B streptococcal (GBS) infection. *Pediatrics*. 1997; 99:489–496. [PubMed: 9041310]
6. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. *MMWR Recomm Rep*. 2002; 51:1–22. [PubMed: 12211284]
7. Committee on Obstetric Practice. Prevention of early-onset group B streptococcal disease in newborns. ACOG Committee Opinion Number 279. *Obstet Gynecol*. 2002; 100:1405–1412. [PubMed: 12468196]
8. Verani JR, McGee L, Schrag SJ. Prevention of Perinatal Group B Streptococcal Disease -- Revised Guidelines from CDC, 2010. *MMWR Recomm Rep*. 2010; 59:1–36. [PubMed: 21088663]
9. American Academy of Pediatrics. Statement of Endorsement–Perinatal Group B Streptococcal Disease. *Pediatrics*. 2010; 127:396.
10. Committee on Obstetric Practice. Prevention of early-onset group B streptococcal disease in newborns. ACOG Committee Opinion Number 485. *Obstet Gynecol*. 2011; 117:1019–1027. [PubMed: 21422882]
11. Committee on Infectious Diseases, Committee on Fetus And Newborn. Recommendations for the prevention of perinatal group B streptococcal (GBS) disease. *Pediatrics*. 2011; 128:611–616. [PubMed: 21807694]
12. Polin RA, Papile L, Baley J, Benitz W, Carlo W, Cummings J, et al. Management of neonates with suspected or proven early-onset bacterial sepsis. *Pediatrics*. 2012; 129:1006–1015. [PubMed: 22547779]
13. Infectious Diseases and Immunization Committee. The prevention of early-onset group B streptococcal infections in the newborn. *Can J Infect Dis*. 1994; 5:251–256. [PubMed: 22346509]
14. Money D, Allen VM. Society of Obstetricians and Gynaecologists of Canada. The prevention of early-onset neonatal group B streptococcal disease. *J Obstet Gynaecol Can*. 2013; 35:939–951. [PubMed: 24165063]
15. Demianczuk NN, Halperin SA, McMillan DD. Prevention of perinatal group B streptococcal infection: Management strategies. *Can J Infect Dis*. 1997; 8:68–70. [PubMed: 22514479]

16. National Collaborating Centre for Women's and Children's Health. Antibiotics for early-onset neonatal infection: antibiotics for the prevention and treatment of early-onset neonatal infection (CG149). London: National Institute for Health and Clinical Excellence; 2012.
17. Rodriguez-Granger J, Alvargonzalez JC, Berardi A, Berner R, Kunze M, Hufnagel M, et al. Prevention of group B streptococcal neonatal disease revisited. The DEVANI European project. *Eur J Clin Microbiol Infect Dis*. 2012; 31:2097–2104. [PubMed: 22314410]
18. Brady MT, Polin RA. Prevention and management of infants with suspected or proven neonatal sepsis. *Pediatrics*. 2013; 132:166–168. [PubMed: 23753101]
19. Mukhopadhyay S, Dukhovny D, Mao W, Eichenwald EC, Puopolo KM. 2010 perinatal GBS prevention guideline and resource utilization. *Pediatrics*. 2014; 133:196–203. [PubMed: 24446442]
20. Malloy MH. Chorioamnionitis: epidemiology of newborn management and outcome United States 2008. *J Perinatol*. 2014; 34:611–615. [PubMed: 24786381]
21. Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. *N Engl J Med*. 2000; 342:15–20. [PubMed: 10620644]
22. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report: Group B streptococcus, 2012. Centers for Disease Control and Prevention; 2013. Available online at <http://www.cdc.gov/abcs/reports-findings/survreports/gbs12.pdf>
23. Cordero L, Rau R, Taylor D, Ayers LW. Enteric gram-negative bacilli bloodstream infections: 17 years' experience in a neonatal intensive care unit. *Am J Infect Control*. 2004; 32:189–195. [PubMed: 15175611]
24. Sanghvi KP, Tudehope DI. Neonatal bacterial sepsis in a neonatal intensive care unit: A 5 year analysis. *J Paediatr Child Health*. 1996; 32:333–338. [PubMed: 8844541]
25. Isaacs D, Barfield CP, Grimwood K, McPhee AJ, Minutillo C, Tudehope DI, et al. Systemic bacterial and fungal infections in infants in Australian neonatal units. *Med J Aust*. 1995; 162:198–201. [PubMed: 7877542]
26. Stoll BJ, Hansen NI, Sanchez PJ, Faix RG, Poindexter BB, Van Meurs KP, et al. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. *Pediatrics*. 2011; 127:817–826. [PubMed: 21518717]
27. Weston EJ, Pondo T, Lewis MM, Martell-Cleary P, Morin C, Jewell B, et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005–2008. *Pediatr Infect Dis J*. 2011; 30:937–941. [PubMed: 21654548]
28. Escobar GJ, Puopolo KM, Wi S, Turk BJ, Kuzniewicz MW, Walsh EM, et al. Stratification of risk of early-onset sepsis in newborns $\geq$ 34 weeks' gestation. *Pediatrics*. 2014; 133:30–36. [PubMed: 24366992]
29. Jackson GL, Rawiki P, Sendelbach D, Manning MD, Engle WD. Hospital course and short-term outcomes of term and late preterm neonates following exposure to prolonged rupture of membranes and/or chorioamnionitis. *Pediatr Infect Dis J*. 2012; 31:89–90. [PubMed: 21860336]
30. Kiser C, Nawab U, McKenna K, Aghai ZH. Role of guidelines on length of therapy in chorioamnionitis and neonatal sepsis. *Pediatrics*. 2014; 133:992–998. [PubMed: 24799549]
31. Bromberger P, Lawrence JM, Braun D, Saunders B, Contreras R, Petitti DB. The influence of intrapartum antibiotics on the clinical spectrum of early-onset group B streptococcal infection in term infants. *Pediatrics*. 2000; 106:244–250. [PubMed: 10920146]
32. Ottolini MC, Lundgren K, Mirkinson LJ, Cason S, Ottolini MG. Utility of complete blood count and blood culture screening to diagnose neonatal sepsis in the asymptomatic at risk newborn. *Pediatr Infect Dis J*. 2003; 22:430–434. [PubMed: 12792384]
33. Hashavya S, Benenson S, Ergaz-Shaltiel Z, Bar-Oz B, Averbuch D, Eventov-Friedman S. The use of blood counts and blood cultures to screen neonates born to partially treated group B Streptococcus-carrier mothers for early-onset sepsis: is it justified? *Pediatr Infect Dis J*. 2011; 30:840–843. [PubMed: 21617574]
34. Flidel-Rimon O, Galstyan S, Juster-Reicher A, Rozin I, Shinwell ES. Limitations of the risk factor based approach in early neonatal sepsis evaluations. *Acta Paediatr*. 2012; 101:e540–e544. [PubMed: 22937988]

35. Cantoni L, Ronfani L, Da Riolo R, Demarini S. Perinatal Study Group of the Region Friuli-Venezia Giulia. Physical examination instead of laboratory tests for most infants born to mothers colonized with group B *Streptococcus*: support for the Centers for Disease Control and Prevention's 2010 recommendations. *J Pediatr*. 2013; 163:568–573. [PubMed: 23477995]
36. Benitz WE, Han MY, Madan A, Ramachandra P. Serial serum C-reactive protein levels in the diagnosis of neonatal infection. *Pediatrics*. 1998; 102:E41. [PubMed: 9755278]
37. Mikhael M, Brown LS, Rosenfeld CR. Serial neutrophil values facilitate predicting the absence of neonatal early-onset sepsis. *J Pediatr*. 2014; 164:522–528. [PubMed: 24331688]
38. Murphy K, Weiner J. Use of leukocyte counts in evaluation of early-onset neonatal sepsis. *Pediatr Infect Dis J*. 2012; 31:16–19. [PubMed: 21860335]
39. Pourcyrous M, Bada HS, Korones SB, Baselski V, Wong SP. Significance of serial C-reactive protein responses in neonatal infection and other disorders. *Pediatrics*. 1993; 92:431–435. [PubMed: 8361798]
40. Gibbs RS, Castillo MS, Rodgers PJ. Management of acute chorioamnionitis. *Am J Obstet Gynecol*. 1980; 136:709–713. [PubMed: 7355955]
41. Benitz WE, Gould JB, Druzin ML. Risk factors for early-onset group B streptococcal sepsis: Estimation of odds ratios by critical literature review. *Pediatrics*. 1999; 103:e77. [PubMed: 10353974]
42. Velaphi S, Siegel JD, Wendel GD Jr, Cushion N, Eid WM, Sanchez PJ. Early-onset group B streptococcal infection after a combined maternal and neonatal group B streptococcal chemoprophylaxis strategy. *Pediatrics*. 2003; 111:541–547. [PubMed: 12612234]
43. Yancey MK, Duff P, Kubilis P, Clark P, Frentzen BH. Risk factors for neonatal sepsis. *Obstet Gynecol*. 1996; 87:188–194. [PubMed: 8559521]
44. Jackson GL, Engle WD, Sendelbach DM, Vedro DA, Josey S, Vinson J, et al. Are complete blood cell counts useful in the evaluation of asymptomatic neonates exposed to suspected chorioamnionitis? *Pediatrics*. 2004; 113:1173–1180. [PubMed: 15121926]
45. Soraisham AS, Singhal N, McMillan DD, Sauve RS, Lee SK, Canadian Neonatal N. A multicenter study on the clinical outcome of chorioamnionitis in preterm infants. *Am J Obstet Gynecol*. 2009; 200:372, e1–e6. [PubMed: 19217596]
46. Pappas A, Kendrick DE, Shankaran S, Stoll BJ, Bell EF, Laptook AR, et al. Chorioamnionitis and early childhood outcomes among extremely low-gestational-age neonates. *JAMA Pediatr*. 2014; 168:137–147. [PubMed: 24378638]
47. Gagliardi L, Rusconi F, Bellu R, Zanini R. Italian Neonatal Network. Association of maternal hypertension and chorioamnionitis with preterm outcomes. *Pediatrics*. 2014; 134:e154–e161. [PubMed: 24913788]
48. Garcia-Munoz Rodrigo F, Galan Henriquez G, Figueras Aloy J, Garcia-Alix Perez A. Outcomes of very-low-birth-weight infants exposed to maternal clinical chorioamnionitis: a multicentre study. *Neonatology*. 2014; 106:229–234. [PubMed: 25011418]
49. Garcia-Munoz Rodrigo F, Galan Henriquez GM, Ospina CG. Morbidity and mortality among very-low-birth-weight infants born to mothers with clinical chorioamnionitis. *Pediatr Neonatol*. 2014; 55:381–386. [PubMed: 24745649]
50. Buckler B, Bell J, Sams R, Cagle W, Bell SA, Allen C, et al. Unnecessary workup of asymptomatic neonates in the era of group B streptococcus prophylaxis. *Infect Dis Obstet Gynecol*. 2010; 2010:1–3.
51. Cuna A, Hakima L, Tseng YA, Fornier B, Islam S, Quintos-Alagheband ML, et al. Clinical dilemma of positive histologic chorioamnionitis in term newborn. *Front Pediatr*. 2014; 2:1–5. [PubMed: 24459665]
52. Puopolo KM, Draper D, Wi S, Newman TB, Zupancic J, Lieberman E, et al. Estimating the probability of neonatal early-onset infection on the basis of maternal risk factors. *Pediatrics*. 2011; 128:e1155–e1163. [PubMed: 22025590]
53. Berardi A, Fornaciari S, Rossi C, Patianna V, Bacchi Reggiani ML, Ferrari F, et al. Safety of physical examination alone for managing well-appearing neonates ≥ 35 weeks' gestation at risk for early-onset sepsis. *J Matern Fetal Neonatal Med*. 2014:1–5. Published online ahead of print. Available at <http://informahealthcare.com/doi/abs/10.3109/14767058.2014.946499>.

54. Escobar GJ, Puopolo KM, Wi S, Turk BJ, Kuzniewicz MW, Walsh EM, et al. Erratum to: Stratification of risk of early-onset sepsis in newborns $\geq$ 34 weeks' gestation. *Pediatrics*. 2014; 134:193.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1Risk Stratification Based on Maternal Risk Factors and Newborn Examination²⁸

	Sepsis Risk at Birth (Cases per 1000 Births)*			
	<0.65	0.65–1.54	1.54	All
Proportion of Cases (%)				
Well appearing	15.6	8.8	7.7	32.0
Equivocal findings	14.4	10.9		25.3
Clinical illness	24.5	18.2		42.7
Total	54.5	45.5		100.0
Proportion of Cohort (%)				
Well appearing	84.7	4.7	0.7	90.1
Equivocal findings	6.4	0.6		7.0
Clinical illness	2.6	0.4		2.9
Total	93.7	6.3		100.0
Attack Rates (/1000 births)				
Well appearing	0.11	1.08	6.74	0.21
Equivocal findings	1.31	11.07		2.11
Clinical illness	5.57	27.10		8.43
Total	0.34	4.18		0.58
Number Needed to Treat				
Well appearing	9370	923	148	4845
Equivocal findings	763	90		474
Clinical illness	180	37		119
Total	2961	239		1722

* Data for infants with prior probabilities of 0.65–1.54 or 1.54 are pooled for those with equivocal findings or clinical illness, due to small sample sizes in the corresponding cells. Values calculated from data of Escobar *et al* in Supplemental Figure 8²⁸ and published erratum⁵⁴.

Table 2

Case Capture and Number Needed to Treat for Sequential Inclusion of Groups Based on Risk Stratification Model²⁸

Group (exam findings and prior probability)	Cumulative % of Cases	Cumulative % of Population	Cumulative NNT
III 0.65	18	0.4	37
+ Equivocal 0.65	29	1.0	57
+ Well 1.54	37	1.6	76
+ III <0.65	61	4.2	117
+ Equivocal < 0.65	76	10.6	241
+ Well 0.65–1.54	84	15.3	312
+ Well < 0.65	100	100.0	1722

Clinical Signs and Laboratory Screening in Ascertainment of Early-Onset Sepsis in Late-Preterm and Term Infants

Table 3

Source	Era	Gestation (weeks)	Births (n)	Symptomatic Infants		Well-appearing Infants		Laboratory Screening ^a		
				n	Cases of EOS ^b	n	Cases of EOS ^b			
Ottolini, 2003 ³²	1996–99	35	19320	300	8	38	19020	0	1665	0
Cantoni, 2013 ³⁵	2005–06	37	7611	44	2	22	7567	0	—	—
Flidel-Rimon, 2012 ³⁴	2005–08	All	22215	434 ^d	20	22	1661 ^d	1	2058	1
Hashavya, 2011 ³³	2005–09	All	53788	N.S.	11 ^e	—	N.S.	0 ^e	1413	0 ^d
Berardi, 2014 ⁴⁹	2009–11	35	19504	80	16	5	N.S.	N.S.	44 ^d	2

^a Screening tests performed in at-risk infants^b Culture-proven cases only^c Cases identified by before appearance of clinical signs^d “At-risk” infants only^e Cases with GBS only

N.S. = not specified